Clinical uses of pegylated pharmaceuticals in oncology

被引：45

作者：

Crawford, J ^{[1
]}

机构：

[1] Duke Univ, Med Ctr, Duke Canc Ctr, Durham, NC 27710 USA

来源：

CANCER TREATMENT REVIEWS | 2002年 / 28卷

关键词：

pegylation; oncology; pegfilgrastim; peginterferon alpha-2a; pegylated liposomal doxorubicin;

D O I：

10.1016/S0305-7372(02)80003-2

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

A number of agents that are used in the treatment of cancer have a suboptimal pharmacokinetic profile that necessitates prolonged or repetitive administration. Pegylation of these agents may help overcome these shortcomings without compromising the agents' efficacy. Several such pegylated agents have now, been developed and evaluated in patients with oncology-related disorders. Pegfilgrastim (a pegylated form of figrastim) has shown efficacy and tolerability that are at least equivalent to those of filgrastim in patients with chemotherapy-induced neutropenia and, unlike unmodified filgrastim, is effective with only one administration per chemotherapy cycle, Other promising pegylated agents are pegylated liposomal doxorubicin, which appears to be more effective and less cardiotoxic than unmodified or liposome-encapsulated doxorubicin, and peginterferon alpha-2a, as once-weekly treatment for renal cell carcinoma. Pegylated agents are likely to be more convenient for patients than the standard formulations, and the improved pharmacokinetics will enhance the clinical utility of these agents. (C) 2002 Elsevier Science. All rights reserved.

引用

页码：7 / 11

页数：5

共 22 条

[1]

Algranati NE, 1999, HEPATOLOGY, V30, p190A

[2]

AVILES A, 2001, P AM SOC CLIN ONCO 2, V20, pB229

[3] Polyethylene glycol-liposomal doxorubicin - A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the management of AIDS-related Kaposi's sarcoma [J].

Coukell, AJ ;

Spencer, CM .

DRUGS, 1997, 53 (03) :520-538

[4]

FISHER M, 2001, CURR TRENDS CYTOKINE, V1, P2

[5] FILGRASTIM - A REVIEW OF ITS PHARMACOLOGICAL PROPERTIES AND THERAPEUTIC EFFICACY IN NEUTROPENIA [J].

FRAMPTON, JE ;

LEE, CR ;

FAULDS, D .

DRUGS, 1994, 48 (05) :731-760

[6] Polyethylene glycol coated (pegylated) liposomal doxorubicin - Rationale for use in solid tumours [J].

Gabizon, A ;

Martin, F .

DRUGS, 1997, 54 (Suppl 4) :15-21

[7]

GREEN M, 2001, P AN M AM SOC CLIN, V20, pA23

[8] Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis [J].

Heathcote, EJ ;

Shiffman, ML ;

Cooksley, WGE ;

Dusheiko, GM ;

Lee, SS ;

Balart, L ;

Reindollar, R ;

Reddy, RK ;

Wright, TL ;

Lin, A ;

Hoffman, J ;

De Pamphilis, J .

NEW ENGLAND JOURNAL OF MEDICINE, 2000, 343 (23) :1673-1680

[9] Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancer [J].

Holmes, FA ;

O'Shaughnessy, JA ;

Vukelja, S ;

Jones, SE ;

Shogan, J ;

Savin, M ;

Glaspy, J ;

Moore, M ;

Meza, L ;

Wiznitzer, I ;

Neumann, TA ;

Hill, LR ;

Liang, BC .

JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (03) :727-731

[10] Randomized, dose-escalation study of SD/01 compared with daily filgrastim in patients receiving chemotherapy [J].

Johnston, E ;

Crawford, J ;

Blackwell, S ;

Bjurstrom, T ;

Lockbaum, P ;

Roskos, L ;

Yang, BB ;

Gardner, S ;

Miller-Messana, MA ;

Shoemaker, D ;

Garst, J ;

Schwab, G .

JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (13) :2522-2528

← 1 2 3 →